MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda...
MSD
MSD Discontinues Vibostolimab and Keytruda Combo Trial in High-Risk Melanoma
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced its decision to cease development of...
MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first...
MSD Partners with Hanmi Pharmaceutical to Develop Combination Therapy for Solid Tumors
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi...
MSD Strikes Deal with GV20 Therapeutics to Test Anti-PD-1 Combo in Solid Tumor Therapies
Merck, Sharp & Dohme (MSD; NYSE: MRK), a global healthcare leader, has entered into a...
Merck Sharp & Dohme Acquires Abceutics for Next-Generation ADC Technology
Global healthcare leader Merck, Sharp & Dohme (MSD) (NYSE: MRK) has secured a strategic acquisition...
MSD’s Winrevair Approved by FDA as First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
The US Food and Drug Administration (FDA) has granted Merck, Sharp & Dohme (MSD; NYSE:...
MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...
Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...
MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...
Gilead and MSD Report Positive Interim Data for Once-Weekly HIV Treatment in Phase II Trial
Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co., Inc., known as MSD (NYSE: MRK),...
Kelun-Biotech Launches Clinical Trials for SKB264, Triggering $75 Million Milestone Payment from MSD
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) has announced the initiation of clinical trials for...
MSD’s Belzutifan and Sperogenix’s Vamorolone Targeted for Priority Review by China’s CDE
The Center for Drug Evaluation (CDE) website has indicated that Merck, Sharp & Dohme’s (MSD;...
Merck’s Keytruda Under Priority Review for New Indication in Endometrial Carcinoma
This week, the U.S. FDA granted priority review status to an indication extension filing from...
MSD’s Keytruda Secures 13th Indication Approval in China for Biliary Carcinoma Treatment
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced that...
Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...
MSD Partners with Variational AI to Harness Generative AI for Drug Discovery
Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...
BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application
The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s...